Effect of cytochrome P450 inhibitors (diethyl dithiocarbamate, ketoconazole and grapefruit juice) on the pharmacokinetics of all-trans-retinoic acid

Farmaco

Volumn 59, Issue 9, 2004, Pages 697-702

  Saadeddin, Anas ^a   Torres Molina, Francisca ^a   Cárcel Trullols, Jaime ^a   Araico, Amparo ^a   Peris, José Esteban ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

All trans retinoic acid; CYP inhibitors; Pharmacokinetics; Rat

Indexed keywords

CYTOCHROME P450 INHIBITOR; DIETHYLDITHIOCARBAMIC ACID; KETOCONAZOLE; RETINOIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; GRAPEFRUIT JUICE; IN VIVO STUDY; MALE; NONHUMAN; RAT; STATISTICAL ANALYSIS;

ANIMALS; BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; ENZYME INHIBITORS; KETOCONAZOLE; RATS; TRETINOIN;

EID: 4344694585     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.04.002     Document Type: Article

References (27)

1. Degos L., Wang Z.Y. All trans retinoic acid in acute promyelocytic leukaemia. Oncogene. 20:2001;7140-7145
2. Fenaux P., Chomienne C., Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin. Hematol. 38:2001;13-25
3. Reynolds C.P., Lemons R.S. Retinoid therapy of childhood cancer. Hematol. Oncol. Clin. North Am. 15:2001;867-910
4. Camacho L.H. Clinical applications of retinoids in cancer medicine. J. Biol. Regul. Homeost. Agent. 17:2003;98-114
5. Conley B.A., Egorin M.J., Sridhara R., Finley R., Hemady R., Wu S., et al. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. 39:1997;291-299
6. Reynolds C.P. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr. Oncol. Rep. 2:2000;511-518
7. Todesco A., Carli M., Iacona I., Frascella E., Ninfo V., Rosolen A. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer. 89:2000;2661-2666
8. Goncalves A., Camerlo J., Bun H., Gravis G., Genre D., Bertucci F., et al. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. 21:2001;1431-1437
9. Goldberg J.S., Vargas M., Rosmarin A.S., Milowsky M.I., Papanicoloau N., Gudas L.J., et al. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 95:2002;1220-1227
10. El Mansouri S., Tod M., Leclero M., Petitjean O., Perret G., Porthault M. Time- and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab. Dispos. 23:1995;227-231
11. Adamson P.C., Bailey J., Pluda J., Poplack D.G., Bauza S., Murphy R.F., et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J. Clin. Oncol. 13:1995;1238-1241
12. Adamson P.C., Reaman G., Finklestein J.Z., Feusner J., Berg S.L., Blaney S.M., et al. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in paediatric patients with refractory cancer. J. Clin. Oncol. 15:1997;3330-3337
13. Regazzi M.B., Iacona I., Gervasutti C., Lazzarino M., Toma S. Clinical pharmacokinetics of tretinoin. Clin. Pharmacokinet. 32:1997;382-402
14. Ahmad M., Nicholls P.J., Smith H.J., Ahmadi M. Effect of P450 isozyme-selective inhibitors on in-vitro metabolism of retinoic acid by rat hepatic microsomes. Pharm. Pharmacol. 52:2000;311-314
15. Singh B.N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 37:1999;213-255
16. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38:2000;41-57
17. Evans A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit. 22:2000;131-136
18. Kane G.C., Lipsky J.J. Drug-grapefruit juice interactions. Mayo Clin. Proc. 75:2000;933-942
19. Saadeddin A., Torres-Molina F., Cárcel-Trullols J., Araico A., Esteban-Peris J. Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats. AAPS PharmSci. 5:(Article 35):2003
20. Torres-Molina F., Peris J.E., Garcia-Carbonell M.C., Aristorena J.C., Granero L., Chesa-Jimenez J. Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Effect of ether anesthesia on absorption of amoxicillin. Arzneimittelforschung. 46:1996;716-719
21. Wagner J.G. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J. Pharm. Sci. 72:1983;838-842
22. Gibaldi M., Perrier D. Pharmacokinetics. 2nd ed :1982;Marcel Dekker Inc., New York
23. Adamson P.C., Boylan J.F., Balis F.M., Murphy R.F., Godwin K.A., Gudas L.J. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Res. 53:1993;472-476
24. Adamson P.C. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer. Leukemia. 8:1994;1813-1816
25. Zerilli A., Ratanasavanh D., Lucas D., Goasduff T., Dreano Y., Menard C., et al. Both cytochromes P450 2E1 and 3A are involved in the O-hydroxylation of p-nitrophenol, a catalytic activity known to be specific for P450 2E1. Chem. Res. Toxicol. 10:1997;1205-1212
26. Yokose T., Doy M., Taniguchi T., Shimada T., Kakiki M., Horie T., et al. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch. 434:1999;401-411
27. Lindell M., Lang M., Lennernas H. Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur. J. Drug Metab. Pharmacokinet. 28:2003;41-48